EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 376 filers reported holding EXELIXIS INC in Q2 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $8,618,661 | +24.6% | 383,563 | +31.6% | 0.00% | +100.0% |
Q1 2024 | $6,916,061 | -5.7% | 291,448 | -4.7% | 0.00% | -50.0% |
Q4 2023 | $7,333,287 | -14.3% | 305,681 | -21.9% | 0.00% | -33.3% |
Q3 2023 | $8,553,423 | +77.5% | 391,461 | +55.2% | 0.00% | +50.0% |
Q2 2023 | $4,818,873 | -46.2% | 252,165 | -45.4% | 0.00% | -50.0% |
Q1 2023 | $8,959,462 | +126.1% | 461,590 | +82.6% | 0.00% | +100.0% |
Q3 2022 | $3,963,000 | +43.8% | 252,789 | +91.0% | 0.00% | +100.0% |
Q2 2022 | $2,756,000 | -76.1% | 132,350 | -74.0% | 0.00% | -75.0% |
Q1 2022 | $11,539,000 | +31.9% | 509,008 | +6.4% | 0.00% | +33.3% |
Q4 2021 | $8,745,000 | -5.5% | 478,376 | +9.2% | 0.00% | 0.0% |
Q3 2021 | $9,257,000 | +7.1% | 437,913 | -7.7% | 0.00% | 0.0% |
Q2 2021 | $8,646,000 | +49.8% | 474,587 | +85.8% | 0.00% | +50.0% |
Q1 2021 | $5,770,000 | -4.0% | 255,431 | -14.7% | 0.00% | -33.3% |
Q4 2020 | $6,011,000 | -8.6% | 299,493 | +11.4% | 0.00% | -25.0% |
Q3 2020 | $6,575,000 | +29.8% | 268,886 | +26.0% | 0.00% | +33.3% |
Q2 2020 | $5,067,000 | +1617.6% | 213,454 | +1147.5% | 0.00% | – |
Q1 2020 | $295,000 | -88.8% | 17,111 | -88.5% | 0.00% | -100.0% |
Q4 2019 | $2,632,000 | +60.6% | 149,353 | +61.2% | 0.00% | 0.0% |
Q3 2019 | $1,639,000 | +69.8% | 92,670 | +105.3% | 0.00% | +50.0% |
Q2 2019 | $965,000 | -74.1% | 45,139 | -71.2% | 0.00% | -66.7% |
Q1 2019 | $3,729,000 | +9.5% | 156,711 | -9.5% | 0.01% | -14.3% |
Q4 2018 | $3,406,000 | +2.4% | 173,133 | -7.8% | 0.01% | 0.0% |
Q3 2018 | $3,327,000 | +140.0% | 187,736 | +191.5% | 0.01% | +75.0% |
Q2 2018 | $1,386,000 | -57.7% | 64,400 | -56.5% | 0.00% | -50.0% |
Q1 2018 | $3,278,000 | -29.5% | 147,998 | -3.3% | 0.01% | -42.9% |
Q4 2017 | $4,652,000 | +31.2% | 153,020 | +4.5% | 0.01% | +27.3% |
Q3 2017 | $3,547,000 | -78.4% | 146,387 | -78.1% | 0.01% | -80.7% |
Q2 2017 | $16,456,000 | +395.7% | 668,102 | +336.1% | 0.06% | +280.0% |
Q1 2017 | $3,320,000 | +64.8% | 153,213 | +13.3% | 0.02% | +87.5% |
Q4 2016 | $2,015,000 | -26.2% | 135,176 | -36.7% | 0.01% | -38.5% |
Q3 2016 | $2,731,000 | +381.7% | 213,557 | +194.0% | 0.01% | +333.3% |
Q2 2016 | $567,000 | +530.0% | 72,649 | +221.3% | 0.00% | +200.0% |
Q1 2016 | $90,000 | -96.6% | 22,609 | -95.1% | 0.00% | -94.1% |
Q4 2015 | $2,624,000 | +4424.1% | 465,253 | +4417.0% | 0.02% | – |
Q3 2015 | $58,000 | -84.7% | 10,300 | -89.8% | 0.00% | -100.0% |
Q2 2015 | $378,000 | -3.3% | 100,562 | -9.1% | 0.00% | -50.0% |
Q1 2014 | $391,000 | – | 110,590 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |